|
22 Mar 2023 |
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
|
|
21 Mar 2023 |
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications
|
|
21 Mar 2023 |
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
|
|
21 Mar 2023 |
Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT886 for Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas
|
|
20 Mar 2023 |
Samsung Bioepis Presents Phase 1 Study Results of SB17 (Ustekinumab), A Proposed Biosimilar to Stelara, at 2023 AAD Annual Meeting
|
|
19 Mar 2023 |
LEO Pharma Presents Late-Breaking Positive Phase 2a Efficacy and Safety Results of LEO 138559 in Moderate-to-Severe Atopic Dermatitis at the 2023 AAD Annual Meeting
|
|
17 Mar 2023 |
Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database
|
|
17 Mar 2023 |
Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously
|
|
16 Mar 2023 |
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
|
|
16 Mar 2023 |
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma
|
|
15 Mar 2023 |
Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma
|
|
14 Mar 2023 |
Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute
|
|
13 Mar 2023 |
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8007, an Antibody-Drug Conjugate Targeting Nectin-4 for the Treatment of Advanced Solid Tumors
|
|
13 Mar 2023 |
ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma
|
|
10 Mar 2023 |
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
|
|
10 Mar 2023 |
Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4
|
|
09 Mar 2023 |
Imfinzi significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable non-small cell lung cancer
|
|
09 Mar 2023 |
Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease
|
|
08 Mar 2023 |
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors
|
|
08 Mar 2023 |
Sales of Therapeutic Antibodies and Proteins in 2022 close to US$ 300 bln with Antibodies contributing more than 80%
|
|
08 Mar 2023 |
Affibody and Chiesi Group collaborate to develop and commercialize innovative treatments for respiratory diseases
|
|
08 Mar 2023 |
Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies Congress
|
|
08 Mar 2023 |
Enthera Pharmaceuticals Initiates Phase 1 Clinical Trial with Lead Candidate Ent001
|
|
07 Mar 2023 |
Anti-Properdin Antibody (NM3086) Demonstrates Efficacy in a Primate Model of Wet-AMD and Dry-AMD
|
|
07 Mar 2023 |
Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy
|
